Literature DB >> 31986971

The Influence of Vestibular Schwannoma Tumor Volume and Growth on Hearing Loss.

Neil S Patel1, Alice E Huang2, Eric M Dowling1, Katherine A Lees1, Nicole M Tombers1, Christine M Lohse3, John P Marinelli2, Jamie J Van Gompel4, Brian A Neff1, Colin L W Driscoll1,4, Michael J Link1,4, Matthew L Carlson1,4.   

Abstract

OBJECTIVE: To ascertain the relationship among vestibular schwannoma (VS) tumor volume, growth, and hearing loss. STUDY
DESIGN: Retrospective cohort study.
SETTING: Single tertiary center. SUBJECTS AND METHODS: Adults with observed VS and serviceable hearing at diagnosis were included. The primary outcome was the development of nonserviceable hearing as estimated using the Kaplan-Meier method. Associations of tumor volume with baseline hearing were assessed using Spearman rank correlation coefficients. Associations of volume and growth with the development of nonserviceable hearing over time were assessed using Cox proportional hazards models and summarized with hazard ratios (HRs).
RESULTS: Of 230 patients with VS and serviceable hearing at diagnosis, 213 had serial volumetric tumor data for analysis. Larger tumor volume at diagnosis was associated with increased pure-tone average (PTA) (P < .001) and decreased word recognition score (WRS) (P = .014). Estimated rates of maintaining serviceable hearing at 6 and 10 years following diagnosis were 67% and 49%, respectively. Larger initial tumor volume was associated with development of nonserviceable hearing in a univariable setting (HR for 1-cm3 increase: 1.36, P = .040) but not after adjusting for PTA and WRS. Tumor growth was not significantly associated with time to nonserviceable hearing (HR, 1.57; P = .14), although estimated rates of maintaining serviceable hearing during observation were poorer in the group that experienced growth.
CONCLUSION: Larger initial VS tumor volume was associated with poorer hearing at baseline. Larger initial tumor volume was also associated with the development of nonserviceable hearing during observation in a univariable setting; however, this association was not statistically significant after adjusting for baseline hearing status.

Entities:  

Keywords:  acoustic neuroma; cranial base; hearing loss; neurotology; skull base; vestibular schwannoma

Year:  2020        PMID: 31986971     DOI: 10.1177/0194599819900396

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  6 in total

1.  The natural history of vestibular schwannoma growth-prospective 40-year data from an unselected national cohort.

Authors:  Martin Reznitsky; Mette Marie Babiel Schmidt Petersen; Niels West; Sven-Eric Stangerup; Per Cayé-Thomasen
Journal:  Neuro Oncol       Date:  2021-05-05       Impact factor: 12.300

2.  Establishment of nomograms for the prediction of useful hearing loss in patients with neurofibromatosis type 2.

Authors:  Shi-Wei Li; Jing Zhang; Han-Lu Tang; Peng Li; Bo Wang; Fu Zhao; Pi-Nan Liu
Journal:  J Neurooncol       Date:  2021-11-09       Impact factor: 4.130

3.  [Hearing classification in patients with vestibular schwannoma using German-language test procedures].

Authors:  T Rahne; S K Plontke; D Vordermark; C Strauss; C Scheller
Journal:  HNO       Date:  2020-09-25       Impact factor: 1.284

4.  Current Understanding of Hearing Loss in Sporadic Vestibular Schwannomas: A Systematic Review.

Authors:  Jinlu Gan; Yanling Zhang; Jingnan Wu; Deqiang Lei; Fangcheng Zhang; Hongyang Zhao; Lei Wang
Journal:  Front Oncol       Date:  2021-08-12       Impact factor: 6.244

5.  Hearing Outcome After Linear Accelerator-Based Radiotherapy for Vestibular Schwannomas: A Retrospective Analysis of a Single Center.

Authors:  Dominique Valérie Clarence de Jel; Ernst J Smid; Tristan P C van Doormaal; Hans G X M Thomeer
Journal:  J Int Adv Otol       Date:  2021-09       Impact factor: 1.017

6.  Long non-coding RNA BRCAT54 sponges microRNA-21 in vestibular schwannoma to suppress cell proliferation.

Authors:  Gang Xiao; Bin Huang; Ming Guo; Chaoxin Long; Pingan Li; Bin Zhong; Chuncheng Guan
Journal:  Bioengineered       Date:  2022-02       Impact factor: 3.269

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.